DEF: Tharimmune Seeks Stockholder Approval for Amended Equity Incentive Plan, Board Nominations Announced

Tharimmune, Inc. is soliciting proxies for its 2025 annual meeting, featuring proposals to elect directors, ratify the appointment of its accounting firm, and approve an amendment to its equity incentive plan.

Summary

• Tharimmune, Inc. is holding its annual meeting of stockholders on June 10, 2025, to vote on several key proposals.
• The proposals include the election of seven directors, ratification of Rosenberg Rich Baker Berman P.A. (RRBB) as the independent registered public accounting firm for the fiscal year ending December 31, 2025, and approval of an amendment to the 2023 Omnibus Equity Incentive Plan.
• The amendment to the equity incentive plan seeks to increase the number of shares of common stock reserved for issuance from 265,353 to 792,602.
• The board of directors recommends voting for all proposals.
• The record date for determining stockholders eligible to vote is April 28, 2025.
• The meeting will be held at 245 Main Street, Suite 245, Chester, NJ 07930.
• Stockholders can vote by internet, mail, or in person at the Annual Meeting.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. It provides necessary information for shareholders to make informed decisions. The positive aspects include the company's commitment to corporate governance and the board's recommendation to vote for all proposals. The potential dilution from the equity incentive plan amendment is a minor negative.

Positives

• The company is committed to good corporate governance practices.
• Four of the seven directors are independent, ensuring objective oversight.
• The board has established audit, compensation, and nominating and corporate governance committees to assist with risk oversight.
• The company has adopted a written code of business conduct and ethics.
• The company prohibits officers, directors, employees and consultants from engaging in hedging or short sales of company securities.

Negatives

• The company does not have a formal policy regarding the separation of its Chair and Chief Executive Officer positions, which could raise concerns about potential conflicts of interest.
• Increasing the number of shares reserved for issuance under the equity incentive plan could dilute existing shareholders' equity.

Risks

• Failure to approve the amendment to the equity incentive plan could limit the company's ability to attract and retain talent.
• The company's success depends on the contributions of its key personnel, and the loss of any of these individuals could harm the business.
• The company operates in a competitive industry, and there is no guarantee that it will be able to maintain its market share.
• The company's financial performance is subject to various risks and uncertainties, including changes in economic conditions, regulatory requirements, and competitive pressures.

Future Outlook

The company anticipates that the additional shares requested under the amendment to the 2023 Plan, plus the remaining shares that are available for issuance under the 2023 Plan, will be sufficient for a period of one year.

Management Comments

• Randy Milby, Chairman of the Board and Chief Executive Officer, cordially invites stockholders to attend the 2025 annual meeting.
• The Board believes that Mr. Milby is best situated to serve as Chairman because he is the director most familiar with the Company's business and industry and is also the person most capable of effectively identifying strategic priorities and leading the discussion and execution of corporate strategy.

Industry Context

The document provides insight into the corporate governance practices, executive compensation, and equity incentive plans of a publicly traded biopharmaceutical company, Tharimmune, Inc., which is relevant to understanding industry standards and practices in the biotech sector.

Comparison to Industry Standards

• The proxy statement provides details on director independence, committee structure, and executive compensation, which are standard disclosures for publicly traded companies.
• The proposed increase in shares reserved for the equity incentive plan is a common practice in the biotech industry to attract and retain talent, but the specific amount and terms should be compared to peer companies.
• The company's corporate governance practices, such as having independent directors and established committees, align with industry best practices.
• The executive compensation structure, including base salary, bonus, and equity awards, is typical for companies of similar size and stage in the biotech industry.
• The company's clawback policy, which allows for the recovery of incentive compensation in the event of a financial restatement, is consistent with regulatory requirements and industry trends.

Management Changes

Corporate Governance

Legal Proceedings

• The document states that the company is not aware of any of its directors or officers being involved in any legal proceedings in the past ten years relating to any matters in bankruptcy, insolvency, criminal proceedings (other than traffic and other minor offenses), or being subject to any of the items set forth under Item 401(f) of Regulation S-K.

Related Party Transactions

• During the fiscal years ended December 31, 2024 and December 31, 2023, the company has not been a party to any transactions in which the amount involved in the transaction exceeds the lesser of $120,000 or 1% of the average of our total assets at year-end for the last two completed fiscal years, or in which any of our directors, executive officers or, to our knowledge, beneficial owners of more than 5% of our capital stock or any member of the immediate family of any of the foregoing persons had or will have a direct or indirect material interest, other than equity and other compensation, termination, change in control and other arrangements, which are described elsewhere in this proxy statement.

Stakeholder Impact

• Shareholders: The proposals directly impact shareholders through voting rights, potential equity dilution, and the selection of board members.
• Employees: The equity incentive plan amendment affects employees' compensation and incentives.
• Customers: No direct impact on customers is mentioned in the document.
• Suppliers: No direct impact on suppliers is mentioned in the document.
• Creditors: No direct impact on creditors is mentioned in the document.

Next Steps

• Stockholders should review the proxy materials and vote on the proposals.
• The company will hold its annual meeting on June 10, 2025.
• The company will file a Form 8-K with the SEC to disclose the final voting results within four business days after the Annual Meeting.

Key Dates

Keywords

proxy statement, annual meeting, directors, equity incentive plan, Rosenberg Rich Baker Berman P.A., RRBB, Tharimmune, stockholders, corporate governance, compensation